期刊文献+

右旋布洛芬糖浆的制备及质量控制 被引量:6

Preparation and Quality Control of Dexibuprofen Syrup
原文传递
导出
摘要 目的:制备右旋布洛芬糖浆,并建立其质量控制方法。方法:以右旋布洛芬为主药制备糖浆;采用高效液相色谱法测定其中主药的含量。结果:所制制剂为淡黄色至黄棕色澄明黏稠液体,检查、鉴别项均符合2005年版《中国药典》中的相关规定。右旋布洛芬检测浓度的线性范围为0.1006~0.5028mg.mL-1(r=0.9999),平均回收率为99.65%(RSD=0.64%)。结论:该制剂制备方法简便可行,质量可控。 OBJECTIVE: To prepare Dexibuprofen Syrup and establish a method for its quality control. METHODS: Dexibuprofen Syrup was prepared with dexibuprofen as main ingredient and the content of dexibuprofen was determined by HPLC. RESULTS: The preparation appeared as yellowish or yellowish-brown sticky liquid and its property was in line with the standard specified in Chinese Pharmacopeia (2005 Edition). The linear range of dexibuprofen was 0.100 6-0. 502 8 mg·mL^-1 (r = 0.999 9) and its average recovery rate was 99.65% (RSD = 0.64%) . CONCLUSION: This preparation is simple and feasible in preparation technology and controllable in quality.
出处 《中国药房》 CAS CSCD 北大核心 2009年第16期1242-1243,共2页 China Pharmacy
关键词 右旋布洛芬糖浆 制备 质量控制 高效液相色谱法 Dexibuprofen syrup Preparation Quality control HPLC
  • 相关文献

参考文献3

  • 1Bon A, Jongejan RC. Treatment of non- malignant pain in the Dutch GP population: an analysis of treatment standards, prescription habits and basic attitudes [J ]. Clin Rheumatol, 2001,20 (Suppl 1) : 225.
  • 2马金龙,赵波,乔连明,周文杰,孙桂珍.布洛芬糖浆剂的研制[J].药学与临床研究,1998,13(4):14-15. 被引量:1
  • 3国家食品药品监督管理局编.国家药品标准(试行)WS-1106(X-834)2002右旋布洛芬[S].2002.

同被引文献42

  • 1游运辉,吴彩玲,高洁生,黄安兰,罗卉.右旋布洛芬栓剂的Ⅱ期临床研究[J].中南大学学报(医学版),2004,29(4):457-459. 被引量:7
  • 2何龙庆,林继成,石冰.菲克定律与扩散的热力学理论[J].安庆师范学院学报(自然科学版),2006,12(4):38-39. 被引量:48
  • 3Brain KR, Green DM, Dykes PJ, et al. The role of men- thol in skin penetration from topical formulations of ibu- profen 5% in vivo[J]. Skin Pharmacol Physiol, 2006, 19 (1):17.
  • 4Chandra A, Sharma PK. NSAIDs dermal delivery: a revi- ew[J]. Pharmaceutical Reviews, 2007,5 (2) : 33.
  • 5王明丽,蒋军,王莉英.直肠给药新制剂的研究进展[J].药学与临床研究,2007,15(5):344-346. 被引量:22
  • 6Algieri C, Drioli E, Donato L. Development of mixed matrix membranes for controlled release of ibuprofen[J]. J Appl Polym Sci, 2013,128(1) : 754.
  • 7Sharma P, Guttikar S, Solanki G, et al. Determination of (S) - ( + ) -and (R) - ( - ) -ibuprofen enantiomers in human plasma after chiral precolumn derivatization by reversed- phase LC-ESI-MS/MS [J]. Bioanalysis, 2012,4 (24) : 2 909.
  • 8Wang JJ, Dai DY, Qiu QQ, et al. Evaluation of anti-in- flammatory and analgesic effects of synthesized deriva- tives of ibuprofen[J]. Chem Biol Drug Des, 2015,85 (5) : 623.
  • 9Yi HG, Chi MH, Kim YI, et al. Formulation of a exten- ded release tablet containing dexibuprofen[J]. Arch Pharm Res,2008,31(12):l 637.
  • 10Kim SR, Kim JK, Park JS, et al. Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability[J]. Int J Pharma, 2011,404 (1/2) : 301.

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部